81. Graft-versus-host Disease Medical Information graftversus-host disease Information from Drugs.com. http://www.drugs.com/enc/graft_versus_host_disease.html

Home New Drugs Latest News Drug Interactions ... Forum Drugs.com - prescription drug and medicine information available on over 24,000 approved- medications and pharmaceuticals, including side effects and drug interactions. Log-in Register Advertisement Buy a Link Now Special Offers From our sponsors Categories Diabetes Gastro Center Weight Loss AIDS/HIV ... Sexual Health Advertisement Advanced Search Or click the first letter of a drug name: A B C D ... Z Graft-versus-host disease Injury Disease Nutrition Poison ... Antibodies Graft-versus-host disease Definition Graft-versus-host-disease is a condition that can occur following bone marrow transplant . The condition may be acute or chronic, mild or severe. Severe cases can often be life-threatening. See also transplant rejection Alternative Names GVHD Causes Bone marrow transplants are performed in specialized hospitals to treat and potentially cure certain types of leukemia or other cancers that have invaded the bone marrow. Doctors also perform experimental bone marrow transplants to treat non-malignant conditions, such as sickle cell anemia. In the transplant, the host's bone marrow is destroyed with chemotherapy or radiation, and then the host receives replacement bone marrow from a donor. Most recipients undergo allogeneic transplants, which means they receive genetically matched bone marrow from a donor, usually a close family member or occasionally someone outside the family who has been found to be a match.

82. Reduction Of Graft-Versus-Host Disease In Mini-Transplants: National Institutes Since graftversus-host disease can be a life threatening and/or life debilitating condition, researchers are now investigating options to reduce the http://patient.cancerconsultants.com/hodgkins_cancer_news.aspx?id=17754

83. Internet Scientific Publications, LLC. The immunologic mechanism of chronic graftversus-host disease (cGvHD) has not Recognition, incidence, and management of oral graft-versus-host disease. http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijd/vol2n1/gvhd.xml

84. U-M Study Finds New Target In War Against Graft-versus-host Disease The risk of graftversus-host disease is highest following a bone marrow transplant from an allogeneic donor - someone other than the patient or the http://www.cancer.med.umich.edu/news/grafthost.htm

U-M Health System U-M Medical School U-M Gateway U-M study finds new target in war against graft-versus-host disease News Archive Media Info News Releases Publications ... U-M CCC in the news Please note: This article is part of the Cancer Center's News Archive, and is listed here for historical purposes. The information and links may no longer be up-to-date. originally posted May 31, 2002 ANN ARBOR, MI - University of Michigan scientists reported this week that they have discovered how graft-versus-host disease, a common and deadly complication of life-saving bone marrow transplants, attacks and often kills its victims. At least 500 Americans die from GVHD every year. The U-M discovery could help prevent these deaths, and reduce the risk of hospitalization and debilitating side-effects for more than 5,000 Americans who receive donor bone marrow transplants annually, primarily to treat leukemia and other cancers. Results from the U-M study, to be published in the June 2002 issue of

85. News Archive: Michigan Oncology Journal Summer 99 The Separation of graftVersus Leukemia and graft-Versus-host disease Through Total body irradiation effects on acute graft versus host disease. http://www.cancer.med.umich.edu/news/moj99su1.htm

U-M Health System U-M Medical School U-M Gateway Michigan Oncology Journal Summer 99 News Archive Michigan Oncology Journal, Summer 99 index From the Editor The Separation of Graft-Versus Leukemia and Graft-Versus-Host Disease Through Cytokine "Shields" Low-Intensity Preparative Regimen and Allogeneic Peripheral Blood Stem Cell Transplantation Stem Cell Transplantation for Multiple Myeloma New Approaches for Neuroblastoma Of Interest Please note: This journal is part of the Cancer Center's News Archive, and is listed here for historical purposes. The information and links may no longer be up-to-date. The Separation of Graft-Versus Leukemia and Graft-Versus-Host Disease Through Cytokine "Shields" James Ferrara, M.D., Professor of Internal Medicine and Pediatrics Director, Blood and Marrow Transplantation Program Allogeneic bone marrow transplantation (BMT) is an effective albeit toxic therapy of many hematologic malignancies. The curative properties of allogeneic BMT derive largely from a graft-versus-leukemia (GVL) effect. Unhappily, the GVL effect is very difficult to dissociate from graft-versus-host disease (GVHD), an often-lethal complication of allogeneic BMT. The separation of GVL from GVHD is therefore an extremely important therapeutic goal of BMT.

86. Graft Versus Host Disease graft Versus host disease. Control of graft Versus host disease graft Versus host disease graft Versus host disease Rare diseases Clinical Trials http://www.ability.org.uk/Graft_Versus_Host_Disease.html

Our Aims Services Stats ... Z Graft Versus Host Disease Control of Graft Versus Host Disease Graft Versus Host Disease Graft Versus Host Disease Rare Diseases Clinical Trials ... Webmaster . Site Design by Ability "see the ability, not the disability" Acknowledgments

87. Graft-versus-host Disease graftversus-host-disease is a condition that can occur following bone marrow graft-versus-host disease occurs when the new donor marrow makes http://adam.about.com/encyclopedia/001309.htm

zJs=10 zJs=11 zJs=12 zJs=13 zc(5,'jsc',zJs,9999999,'') zCMt='a00' About Healthcare Center Healthcare Center Essentials ... Help w(' ');zau(256,140,140,'el','http://z.about.com/0/ip/417/C.htm','');w(xb+xb+' ');zau(256,140,140,'von','http://z.about.com/0/ip/496/7.htm','');w(xb+xb); Search Healthcare Center ENCYCLOPEDIA INDEX Injury Disease Nutrition Poison ... Z Graft-versus-host disease Overview Symptoms Treatment Prevention Definition: Graft-versus-host-disease is a condition that can occur following bone marrow transplant . The donor's immune cells in the transplanted marrow make antibodies against the host's (transplant patient's) tissues and attack the patient's vital organs. The condition may be acute or chronic, mild or severe. Severe cases can often be life-threatening. See also transplant rejection Alternative Names: GVHD Causes, incidence, and risk factors: Bone marrow transplants are performed in specialized hospitals to treat and potentially cure certain types of leukemia or other cancers that have invaded the bone marrow. Doctors also perform experimental bone marrow transplants to treat non-malignant conditions, such as sickle cell anemia. In the transplant, the host's bone marrow is destroyed with chemotherapy and/or radiation, and then the host receives replacement bone marrow from a donor. Most recipients undergo allogeneic transplants, which means they receive genetically matched bone marrow from a donor, usually a close family member or occasionally someone outside the family who has been found to be a match.

88. UpToDate Prevention And Treatment Of Acute Graft-versus-host Disease: Recommenda INTRODUCTION — Clinically significant acute graftversus-host disease (GVHD) occurs in 9 to 50 percent of patients who receive an allogeneic hematopoietic http://patients.uptodate.com/topic.asp?file=hcell_tr/5229

89. UpToDate Treatment Of Chronic Graft-versus-host Disease INTRODUCTION — graftversus-host disease (GVHD) is divided into acute and chronic (See Prevention and treatment of acute graft-versus-host disease http://patients.uptodate.com/topic.asp?file=hcell_tr/7404

90. University Of Florida Shands Cancer Center Reduction Of Graft Reduction of graftVersus-host disease in Mini-Transplants National Institutes of Since graft-versus-host disease can be a life threatening and/or life http://www.ufscc.ufl.edu/cancernews.aspx?section=cancernews&id=17754

91. National Cancer Institute - NCI HTML Cancer Bulletin For May 31, 2005 Preventing graftversus-host disease during Hematologic Cancer Treatment. Name of the Trial Randomized Pilot Study of Donor Th2 Cells Generated In Vitro by http://www.cancer.gov/ncicancerbulletin/NCI_Cancer_Bulletin_053105/page6

var bSearchBoxBool=false; www.cancer.gov May 31, 2005 • Volume 2 / Number 22 E-Mail This Document Download PDF Bulletin Archive/Search Subscribe ... Bulletin Home Featured Article More Evidence Links Statins to Cancer Prevention Director's Update Now More Than Ever: Positive Health Strategies Make a Difference Spotlight Melanoma Update: Recent Advances in Research Cancer Research Highlights MRI Detects Breast Tumors in High-Risk Women Study Links Obesity to Aggressive Prostate Cancer Broken Bones, Osteoporosis Protect Against Ovarian Cancer Colonoscopy May be Superior to Sigmoidoscopy in Many Women ... Blood Stem Cells Linked to ALL Featured Clinical Trial Preventing Graft-versus-Host Disease during Hematologic Cancer Treatment Funding Opportunities Notes Science Writers' Seminar to Showcase Blood-Borne Cancers New Glycemic Index Values Database Released Small Grants Program Grantee Meeting ENACCT to Fund Clinical Trials Education Activities ... CCR Grand Rounds Community Update An Overview of States with Laws Related to Third-Party Coverage for Cervical Cancer Screening (as of September 30, 2004) Bulletin Archive Page Options Print This Page Print This Document View Entire Document E-Mail This Document ... View/Print PDF Preventing Graft-versus-Host Disease during Hematologic Cancer Treatment Name of the Trial Randomized Pilot Study of Donor Th2 Cells Generated In Vitro by Sirolimus Treatment with or without Oral Sirolimus versus Oral Sirolimus Alone for Prevention of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies (NCI-04-C-0055). See the protocol summary at

92. National Cancer Institute - Dictionary Of Cancer Terms An inherited increase in the risk of developing a disease. graftversus-host disease. A reaction of donated stem cells against the patient’s tissue. http://www.cancer.gov/templates/db_alpha.aspx?expand=G

93. Graft Versus Host Disease,: CD4+ T Cells Mediate Syngeneic Graft-versus-host Dis OBGYN.net Headline News page, daily womens health news. http://www.obgyn.net/newsheadlines/headline_medical_news-Graft_versus_Host_Disea

HEADLINE NEWS - Featured Sections - Adhesions Advertising Opportunities Breast Care CME - available free online Contraception Endometriosis Zone Fetal Monitoring First Gyne Exam Tutorial Gynecological Oncology IVF Treatment Tutorial Infertility Menopause Nursing Osteoporosis PCOS Pelvic Pain Physicians-in-Training PMS/PMDD Sex-Related Issues Technology Ultrasound Urogynecology Weight Management Young Woman Home Medical Professionals Women's Pavilion Industry Professionals Asia Europe Latina Middle East Country Pages Sign up for OBGYN.net e-mail Newsletters Career Search Site Update Free Email Newsletter Health News Headlines Quick Links Acronym Expander Bibliography Bookstore Member Webpages ... PowerPoint Presentations Practice Tools Build your own web page Employment Opportunities Find a CV Medical Web Sites ... Image Library Conference Calendar OB-GYN Calendar OB-GYN Upcoming Meetings Conference Coverage Conference Interviews Book of Proceedings from COGI 99 Medical Resources Academic Departments of OBGYN Academic Links Acronyms Explained Associations and Societies ... Student Resources News and Views Free Email Newsletter Today's News Media Page Vendor Directory Add your company Search Equipment Pharmaceutical ... Supplies Global Latina Europe Country Pages U. S. Information

94. Drugs Limit Deadly Side Effects Of Graft-versus-host Disease A new class of anticancer drugs, currently being tested in human clinical trials, reduces the severity of graft-versus-host disease or GVHD — a common and http://www.eurekalert.org/pub_releases/2004-02/uomh-dld022704.php

Public release date: 27-Feb-2004 E-mail Article Contact: Sally Pobojewski pobo@umich.edu University of Michigan Health System Drugs limit deadly side effects of graft-versus-host disease Could make bone marrow transplants an option for more cancer patients ANN ARBOR, MI ¡V A new class of anti-cancer drugs, currently being tested in human clinical trials, reduces the severity of graft-versus-host disease or GVHD — a common and often deadly complication of life-saving bone marrow transplants — without suppressing the immune response required to kill lingering cancer cells. Scientists at the University of Michigan's Comprehensive Cancer Center are the first to study the effect of these drugs, called HDAC inhibitors, in laboratory mice with cancer after the mice received a bone marrow transplant. Results of the U-M study were published online in this week's early edition of the Proceedings of the National Academy of Sciences Other studies have shown that high doses of HDAC inhibitors can be an effective anti-tumor agent in mice and humans. Now, U-M scientists have found that low doses of the same drugs have a powerful anti-inflammatory effect. This prevents the production of proteins called inflammatory cytokines, which cause the extensive cell damage seen in GVHD patients. "What's so exciting is that HDAC inhibitors already have been tested as a chemotherapeutic agent in people," says co-author James L.M. Ferrara, M.D., director of the U-M's Blood and Marrow Transplant Program and a professor of internal medicine and pediatrics in the U-M Medical School. "They have relatively little toxicity and the doses required to generate an anti-inflammatory effect are 50- to 100-fold lower than doses needed to kill cancer cells."

95. Disease Category Listing (550): Graft-Versus-Host Disease (GVHD) CenterWatch Listing of Clinical Research Trials for graftVersus-host disease (GVHD) http://www.centerwatch.com/patient/studies/cat550.html

Clinical Trials: Graft-Versus-Host Disease (GVHD) California Duarte; City of Hope National Medical Center A Pilot Study of Sirolimus and Tacrolimus as Graft-Versus-Host-Disease Prophylaxis in Patients undergoing HLA-Matched Donor Hematopoietic Stem Cell Transplantation Duarte; City of Hope National Medical Center A Multi-Center Phase III Double-Blind Clinical Trial to Evaluate the Efficacy of Mycophenolate Mofetil added to Prednisone plus Cyclosporine or Tacrolimus for Treatment of Newly Diagnosed Chronic Graft Vs Host Disease Back to Clinical Trials by Medical Areas Research centers specializing in this illness area Additional resources ... in this illness area This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Trial listing updated: September 21, 2005 at 2:33:10 PM

96. Acute Graft-versus-host Disease In Thalassaemic Marrow Transplantation With Low- graftversus-host disease (GVHD) prophylaxis was cyclosporin, prednisolone and low-dose antithymocyte globulin. Our patient data showed a low incidence of http://www.emro.who.int/Publications/EMHJ/0503/05.htm

Eastern Mediterranean Health Journal Back to Health Journal page Health Journal back issues Home Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin H.N. Khojasteh, M. Zakerinia, M. Ramzi and M. Haghshenas Volume 5, Issue 3, 1999, Page 465-469 Abstract Our unit performed transplantations on 21 classes II and III thalassaemic patients (class II patients had either hepatomegaly or portal fibrosis and class III patients had both ). We used busulfan (15 mg/kg) and cyclophosphamide (200 mg/kg). Graft-versus-host disease (GVHD) prophylaxis was cyclosporin, prednisolone and low-dose antithymocyte globulin. Our patient data showed a low incidence of acute GVHD following transplantation. We offer this regimen as an acceptable therapy for thalassaemic patients undergoing allogeneic marrow transplantation as a safe clinical procedure, irrespective of the class of patient. Réaction du greffon contre l'hôte dans la greffe de moelle osseuse chez des patients thalassémiques avec administration d'une globuline antithymocytes à faible dose RESUME Notre service a effectué des transplantations chez 21 patients thalassémiques de classe II et III (les patients de classe II avaient soit une hépatomégalie soit une fibrose porte et les patients de classe III avaient les deux). Nous avons utilisé le busulfan (15 mg/kg) et la cyclophosphamide (200 mg/kg). La prophylaxie pour la réaction du greffon contre l'hôte comportait la ciclosporine, la prednisolone et l'administration d'une globuline antithymocytes à faible dose. Les données relatives à nos patients ont indiqué une faible incidence de la réaction du greffon contre l'hôte (rejet aigu) après une transplantation. Nous proposons ce schéma thérapeutique comme traitement acceptable pour les patients thalassémiques subissant une greffe de moelle osseuse allogénique en tant que procédure clinique sans danger, quelle que soit de la classe des patients.

97. MedlinePlus Medical Encyclopedia: Graft-versus-host Disease graftversus-host-disease is a condition that can occur following bone marrow Varying degrees of graft-versus-host disease are viewed as an expected http://www.nlm.nih.gov/medlineplus/ency/article/001309.htm

@import url(/medlineplus/images/advanced.css); Skip navigation Medical Encyclopedia Other encyclopedia topics: A-Ag Ah-Ap Aq-Az B-Bk ... Z Graft-versus-host disease Contents of this page: Illustrations Alternative names Definition Causes, incidence, and risk factors ... Prevention Illustrations Antibodies Alternative names Return to top GVHD Definition Return to top Graft-versus-host-disease is a condition that can occur following bone marrow transplant . The condition may be acute or chronic, mild or severe. Severe cases can often be life-threatening. See also transplant rejection Causes, incidence, and risk factors Return to top Bone marrow transplants are performed in specialized hospitals to treat and potentially cure certain types of leukemia or other cancers that have invaded the bone marrow. Doctors also perform experimental bone marrow transplants to treat non-malignant conditions, such as sickle cell anemia. In the transplant, the host's bone marrow is destroyed with chemotherapy or radiation, and then the host receives replacement bone marrow from a donor. Most recipients undergo allogeneic transplants, which means they receive genetically matched bone marrow from a donor, usually a close family member or occasionally someone outside the family who has been found to be a match. Sometimes, autologous transplants are performed. Here, the person is given back his or her own marrow once it has been purged of malignant cells.

98. Photopheresis As A Treatment Of Autoimmune Disease And Graft-versus-Host Disease The use of photopheresis as a treatment of graftversus-host disease Refractory disease is defined as chronic graft-versus-host disease that fails to http://www.regence.com/trgmedpol/medicine/med84.html

Policies TRG Medical Policy TRG Dental Policy TRG Behavioral Health Policy Medicine Section - Photopheresis as a Treatment of Autoimmune Disease and Graft-versus-Host Disease Topic: Photopheresis as a Treatment of Autoimmune Disease and Graft-versus-Host Disease Date of Origin: Section: Medicine Policy No: Approved Date: Effective Date: Next Review Date: IMPORTANT REMINDER This Medical Policy has been developed through consideration of medical necessity, generally accepted standards of medical practice, and review of medical literature and government approval status. Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. The purpose of medical policy is to provide a guide to coverage. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Description Photopheresis is a multistep procedure involving the following: Patients ingest the drug psoralen, which functions to render cells (including lymphocytes) light sensitive.

99. NEJM -- Graft-versus-host Disease And Survival In Patients With Aplastic Anemia Original Article from The New England Journal of Medicine graftversus-host disease and survival in patients with aplastic anemia treated by marrow http://content.nejm.org/cgi/content/abstract/308/6/302

// var NTPT_PGEXTRA = ''; // var NTPT_PGREFTOP = false; // var NTPT_NOINITIALTAG = false; HOME SEARCH CURRENT ISSUE PAST ISSUES ... HELP Please sign in for full text and personal services Previous Volume 308:302-307 February 10, 1983 Number 6 Next Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment R Storb, RL Prentice, CD Buckner, RA Clift, F Appelbaum, J Deeg, K Doney, JA Hansen, M Mason, JE Sanders, J Singer, KM Sullivan, RP Witherspoon, and ED Thomas Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited ... PubMed Citation Abstract This article has been cited by other articles: Iwasaki, T. (2004). Recent Advances in the Treatment of Graft-Versus-Host Disease. Clin Med Res [Abstract] [Full Text] Baron, F., Maris, M. B., Sandmaier, B. M., Storer, B. E., Sorror, M., Diaconescu, R., Woolfrey, A. E., Chauncey, T. R., Flowers, M. E.D., Mielcarek, M., Maloney, D. G., Storb, R. (2005). Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning. J Clin Oncol [Abstract] [Full Text] Storb, R. F., Lucarelli, G., McSweeney, P. A., Childs, R. W. (2003). Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors.

100. NEJM -- Graft-versus-host Disease As Adoptive Immunotherapy In Patients With Adv Original Article from The New England Journal of Medicine graftversus-host disease as adoptive immunotherapy in patients with advanced hematologic http://content.nejm.org/cgi/content/abstract/320/13/828

// var NTPT_PGEXTRA = ''; // var NTPT_PGREFTOP = false; // var NTPT_NOINITIALTAG = false; HOME SEARCH CURRENT ISSUE PAST ISSUES ... HELP Please sign in for full text and personal services Previous Volume 320:828-834 March 30, 1989 Number 13 Next Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms KM Sullivan, R Storb, CD Buckner, A Fefer, L Fisher, PL Weiden, RP Witherspoon, FR Appelbaum, M Banaji, J Hansen, and et al. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited ... PubMed Citation Abstract Source Information Fred Hutchinson Cancer Research Center, Seattle, WA. This article has been cited by other articles: Kolb, H.-J., Schmid, C., Barrett, A. J., Schendel, D. J. (2004). Graft-versus-leukemia reactions in allogeneic chimeras. Blood [Abstract] [Full Text] Hinterberger, W., Rowlings, P. A., Hinterberger-Fischer, M., Gibson, J., Jacobsen, N., Klein, J. P., Kolb, H.-J., Stevens, D. A., Horowitz, M. M., Gale, R. P. (1997). Results of Transplanting Bone Marrow from Genetically Identical Twins into Patients with Aplastic Anemia. Ann Intern Med [Abstract] [Full Text] Cooper, L. J. N., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W.-C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S. J., Jensen, M. C. (2003). T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-100 of 104    Back | 1  | 2  | 3  | 4  | 5  | 6  | Next 20